



INVITED SPEAKER PRESENTATION

Open Access

PReS13-SPK-1587: New biologic targets for the future and basic science behind them

B Prakken

From 20th Pediatric Rheumatology European Society (PReS) Congress
Ljubljana, Slovenia. 25-29 September 2013

The treatment of paediatric rheumatic diseases has made great progress in the last decade. The introduction of the biologicals meant (after the introduction of MTX) the second therapeutic revolution. This together with many improvements in related areas has greatly improved the quality of life of patients with rheumatic diseases. At present however, despite the introduction of more biological agents directed at immune targets the progression has stalled. The next challenge will be to:

- 1) Better understand the immune pathogenesis underlying the heterogeneity of the disease.
- 2) Identify patients at risk at the onset of disease and stratify them according to risk factors.
- 3) Personalize treatment based on their risk profiling.
- 4) Develop strategies that are aimed not only at suppressing disease but also at maintaining disease remission after withdrawing immune suppression.

Over the last years much progress has been made in all these areas. In this presentation we will discuss this progress, focusing on a better understanding of the mechanisms of immune tolerance, leading to new targets for intervention.

Disclosure of interest

B. Prakken Grant/Research Support from: Dutch Arthritis Foundation.

Published: 5 December 2013

References

1. Zonneveld-Huijssoon E, et al: TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis. *Annals of the rheumatic diseases* 2012, **71**(10):1706-1715.
2. Wehrens E, et al: T cells out of control-impaired immune regulation in the inflamed joint. *Nature reviews. Rheumatology* 2012, doi:10.1038/nrrheum.2012.149.

Pediatric Immunology, University Medical Centre Utrecht, Utrecht, Netherlands

3. Albani S, et al: Induction of immune tolerance in the treatment of rheumatoid arthritis. *Nature reviews. Rheumatology* 2011, **7**(5):272-281.
4. Prakken B, et al: In Juvenile idiopathic arthritis. Volume 377. *Lancet*; 2011;(9783):2138-2149.

doi:10.1186/1546-0096-11-S2-117

Cite this article as: Prakken: PReS13-SPK-1587: New biologic targets for the future and basic science behind them. *Pediatric Rheumatology* 2013 **11** (Suppl 2):117.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

